Total trials
1,251
Active
545
Phase 3
183
Total enrollment
2,269,124
Pipeline matrix
Showing 40 of 526 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Capecitabine | — | 51 | |||||
| Huaier Granule | — | — | — | — | 8 | ||
| Tunlametinib | — | — | — | — | 2 | ||
| Dexmeditomidine | — | — | — | — | — | 1 | |
| Esketamine | — | — | — | — | — | 1 | |
| Anlotinib and Bevacizumab | — | — | — | — | — | 1 | |
| Systematic chemotherapy | — | — | — | — | — | 1 | |
| Intrathecal chemotherapy | — | — | — | — | — | 1 | |
| Befotertinib | — | — | — | — | — | 1 | |
| Tongxinluo | — | — | — | — | — | 1 | |
| Canagliflozin group | — | — | — | — | — | 1 | |
| Sitagliptin | — | — | — | — | — | 1 | |
| Acarbose | — | — | — | — | — | 1 | |
| Inetetamab and Paclitaxel ± Pertuzumab | — | — | — | — | — | 1 | |
| dabrafenib plus trametinib with or without PD-1 antibody | — | — | — | — | — | 1 | |
| entrectinib or larotrectinib with or without anti-PD-1 antibdoy | — | — | — | — | — | 1 | |
| pralsetinib or selpercatinib with or without anti-PD-1 antibdoy | — | — | — | — | — | 1 | |
| anlotinib or anlotinib plus anti-PD-1 antibody | — | — | — | — | — | 1 | |
| lenvatinib plus anti-PD-1 antibody | — | — | — | — | — | 1 | |
| Other Targets: precise treatment based on the target | — | — | — | — | — | 1 | |
| propofol | — | — | — | — | 2 | ||
| Oxaliplatin | — | — | — | — | 33 | ||
| Camrelizumab | — | — | — | 19 | |||
| Chemotherapy | — | — | — | 19 | |||
| Paclitaxel | — | — | — | — | 18 | ||
| Gemcitabine | — | — | — | — | 21 | ||
| Carboplatin | — | — | — | — | 13 | ||
| SHR-A1811 | — | — | — | — | 9 | ||
| Trastuzumab | — | — | — | — | 13 | ||
| Nab paclitaxel | — | — | — | — | 12 | ||
| Cyclophosphamide | — | — | — | — | 12 | ||
| Adebrelimab | — | — | 9 | ||||
| Fluzoparib | — | — | — | — | 9 | ||
| Epirubicin | — | — | — | 11 | |||
| Docetaxel | — | — | — | — | 16 | ||
| Cisplatin | — | — | — | — | 14 | ||
| Famitinib | — | — | — | — | 7 | ||
| Apatinib | — | — | — | 15 | |||
| Nab-paclitaxel | — | — | — | — | 10 | ||
| PD-1 inhibitor | — | — | — | 5 |
486 more active programs hidden
Next readouts
- 2022-01-01
- 2022-05
- 2023-09-01
- 2023-12
- 2024-03-12
- 2024-03-30
- 2024-05-20
- 2024-06
- 2024-06
- 2024-07-11
Top conditions
- Breast Cancer145
- Colorectal Cancer58
- Hepatocellular Carcinoma33
- Gastric Cancer30
- Esophageal Squamous Cell Carcinoma28
- Pancreatic Cancer25
- Metastatic Breast Cancer25
- Nasopharyngeal Carcinoma21
Frequently asked questions about Fudan University
- How many clinical trials does Fudan University have on ClinicalTrials.gov?
- Fudan University is listed as the lead sponsor on 1,251 clinical trials in ClinicalTrials.gov, 545 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fudan University's trials are in Phase 3?
- 183 of Fudan University's trials are in Phase 3, spread across 526 active drug programs.
- What therapeutic areas does Fudan University focus on?
- Fudan University's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Gastric Cancer, Esophageal Squamous Cell Carcinoma.
- When are Fudan University's next clinical trial readouts?
- Fudan University has 10 upcoming primary-completion readouts tracked here; the soonest is “S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC）”, expected around 2022-01-01.